On February 10, 2020 Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, reported that it will release its fourth quarter and year-end financial results on Tuesday, February 25, 2020 (Press release, Insmed, FEB 10, 2020, View Source [SID1234554123]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Insmed management will host a conference call for investors beginning at 8:30 a.m. ET on Tuesday, February 25, 2020 to discuss the financial results and provide a business update.

Shareholders and other interested parties may participate in the conference call by dialing (888) 317-6003 (domestic) or (412) 317-6061 (international) and referencing conference ID number 3317351. The call will also be webcast live on the company’s website at www.insmed.com.

A replay of the conference call will be accessible approximately one hour after its completion through March 3, 2020 by dialing (877) 344-7529 (domestic) or (412) 317-0088 (international) and referencing replay access code 10139238. A webcast of the call will also be archived for 90 days under the Investor Relations section of the company’s website at www.insmed.com.

On February 10, 2020 Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (NASDAQ: CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, reported that the Company will present at Noble Capital Markets’ 16th Annual Investor Conference on Monday, February 17, 2020 at 4:00 PM ET (Press release, Citius Pharmaceuticals, FEB 10, 2020, View Source [SID1234554122]). The conference is being held at the Seminole Hard Rock Hotel & Casino in Hollywood, Florida on February 16-18, 2020.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Event: Noble Capital Markets’ 16th Annual Investor Conference

Presentation Date: Monday, February 17, 2020

Presentation Time: 4:00 PM ET – Terrace Ballroom A

Location: Seminole Hard Rock Hotel & Casino – Hollywood, FL

Mr. Leonard Mazur, Chairman of Citius, will deliver an update on the Company, including a discussion of the recent positive outcome of its interim futility analysis for the Phase 3 Mino-Lok pivotal trial, and provide an overview of its other pipeline products, Mino-Wrap and Halo-Lido. Additionally, Mr. Mazur will also be available at the conference for one-on-one meetings with investors. To arrange a meeting with the Company, please contact Mr. Andrew Scott: [email protected].

Mr. Mazur’s presentation will be available for playback at the link below approximately 24 hours following his live address and be archived for 90 days following the conference: View Source

This is the 16th year Noble Capital Markets has hosted "NobleCon" and invited emerging growth companies to present to and meet with attending investors. NobleCon will feature approximately 125 small growth companies presenting across four tracks occurring simultaneously, company executives meeting with investors in 1×1/face-to-face formats, and special panel sessions featuring key opinion leaders on topics such as cannabis, biotechnology, and mining, just to name a few. Noble Capital Markets will be broadening access to investors worldwide by hosting the conference site on Channelchek.com, its web-based market platform that emphasizes emerging growth companies.

On February 10, 2020 International Isotopes Inc. (OTCQB: INIS) (the "Company") is reported it has received approval from the U.S. Food and Drug Administration (FDA) for its SODIUM IODIDE I-131 pharmaceutical product (Press release, Institute of Isotopes, FEB 10, 2020, View Source [SID1234554121]). SODIUM IODIDE I-131 is a radioactive therapeutic agent indicated for the treatment of hyperthyroidism and carcinoma of the thyroid. The American Cancer Society estimates more than fifty thousand adults in the United States are diagnosed with thyroid cancer each year.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Steve T. Laflin, President and CEO of the Company, said, "We are very pleased to have gained FDA approval of this important pharmaceutical product, which is the only FDA approved generic product of its type manufactured in the United States. INIS has long established itself as a reliable supplier of radiochemicals and we have earned a reputation for high quality products and excellent customer service. Extending our reach to provide FDA approved products is a logical extension of our current supply arrangements. INIS has several additional products at various stages of development in our pipeline. With the successful FDA approval of our first pharmaceutical product, we look forward to utilizing SODIUM IODIDE I-131 as a springboard to advance additional products we have under development. SODIUM IODIDE I-131 will be an important addition to the Company’s product offerings, and we anticipate launching commercial distribution in the very near future."

About INIS’s Sodium Iodide I-131 Product
Radiochemical Sodium Iodide I-131 is utilized for the preparation of sodium iodide I-131 capsules and solution. To use Sodium Iodide I-131 safely and effectively please see the full prescribing information for Sodium Iodide I-131 included in product labeling as well as all warnings, precautions, possible adverse reactions, and drug interactions.

On February 10, 2020 Sirtex Medical US Holdings, Inc. ("Sirtex"), a leading manufacturer of targeted liver cancer therapies, reported that the shareholders of OncoSec Medical, Inc. ("OncoSec") have approved, and the parties have closed, the strategic investment by and partnership with Sirtex and Grand Decade Developments Limited, a wholly owned subsidiary of China Grand Pharmaceutical and Healthcare Holdings Limited ("CGP") (Press release, Sirtex Medical, FEB 10, 2020, View Source [SID1234554120]). The signing of the strategic transaction was previously announced on October 10, 2019.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

As a result of the transaction, Sirtex acquired approximately 8.8% of the outstanding shares of common stock of OncoSec and will also support and assist OncoSec with pre-marketing activities for its TAVO and Visceral Lesion Applicator (VLA) products in exchange for low single-digit royalties. In addition, CGP acquired approximately 44% of the outstanding shares of common stock of OncoSec and entered into an exclusive license to OncoSec’s products in Greater China and other Asian countries in exchange for a royalty. More details of the transaction documents can be found in OncoSec’s filings with the U.S. Securities and Exchange Commission.

"Sirtex is excited to close this transaction with OncoSec and to assist in efforts to bring its innovative products to fight cancer to the market," said Kevin Smith, Chief Executive Officer of Sirtex. "OncoSec, CGP and Sirtex are committed to improving treatment outcomes for patients and this transaction demonstrates that shared commitment."

On February 10, 2020 Diverse Biotech, Inc. www.diversebiotech.com has reported it has been selected to present at the upcoming BIO CEO & Investor Conference in New York on February 11th. View Source (Press release, Diverse Biotech, FEB 10, 2020, View Source [SID1234554119])

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

In addition, Diverse Biotech has announced that a paper regarding cannabinoid-related gene expression was accepted by the Journal of Applied Cell Biology. The paper should be published in the next 3-4 weeks.

"We are truly excited to continue to discuss our ground-breaking technology. In addition, the gene expression paper is tremendous because it highlights that a variety of cell lines including glioblastoma, pancreatic cancer, melanoma, actinic keratosis, squamous cell carcinoma, and normal skin – all express genes that suggest they will be responsive to exogenous cannabinoid treatment," said Stella Vnook, Diverse Biotech’s Chief Executive Officer.